Clinical trial

Blood Pressure, Cerebral Blood Flow and Cognition in SCI

Name
WEC-13-066
Description
Following spinal cord injury autonomic regulation of the cardiovascular system is impaired, which results in a variety of measurable abnormalities in blood pressure. Evidence of causality has been documented in the general medical literature with findings of improved cognitive function following acute increases in blood pressure using the anti-hypotensive agent Midodrine Hydrochloride (midodrine). Additionally, a recent report documented an inverse association between blood pressure and depression suggesting that low blood pressure may confer greater risk than high blood pressure. Midodrine is a drug approved by the Food and Drug Administration to treat low blood pressure in the general population. Midodrine is not approved in the United States to treat low blood pressure in persons with spinal cord injury. Therefore, its use in this study is investigational. The first objective is to characterize the relationship between blood pressure, cerebral blood flow velocity and cognitive function after a single dose of midodrine compared to placebo. Second objective is to determine the long-term safety and efficacy of midodrine administration.
Trial arms
Trial start
2014-03-01
Estimated PCD
2019-12-01
Trial end
2019-12-01
Status
Completed
Phase
Early phase I
Treatment
Midodrine
Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Arms:
Midodrine, Placebo
Other names:
Midodrine or Placebo
Placebo
Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
Arms:
Midodrine, Placebo
Other names:
Midodrine or Placebo
Size
60
Primary endpoint
Systolic Blood Pressure
Up to 3 years
Eligibility criteria
Inclusion Criteria: Spinal Cord Injured * Between the ages of 18-65 years old. * Level of injury is between C1-T12 * Primarily wheelchair dependent for ambulation * Have a spinal cord injury that is ASIA Impairment Scale (AIS) grade of A, B or C * Injury occurred more than 1 year ago * Low blood pressure (Systolic BP less than 110 mmHg for males, Systolic BP less than 100 mmHg for females) * Primary language is English * I am right handed Exclusion Criteria: * Currently have an illness or infection * Severe history of AD (more than 3 symptomatic events per week, evidence of blood pressure elevations above 140/90 mmHg,significant adverse subjective symptoms reporting) * Hypertension or diabetes * History of Traumatic Brain Injury (TBI) * Neurological condition other than SCI (Alzheimer's disease, dementia, stroke, multiple sclerosis, Parkinson's disease, etc.) * History of epilepsy or other seizure disorder * Diagnosis of a psychiatric disorder such as post-traumatic stress disorder, schizophrenia or bipolar disorder * Within the past 6 months, abused illicit drugs * Pre-screen mini mental status exam score of less than 24, as rated by the researcher * Vision is impaired- more than 20/60 in worst eye (with prescription eyewear) * Coronary heart and/or artery disease * Major surgery in the last 30 days * Pregnant
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}
Updated at
2023-06-28

1 organization

1 product

1 drug

1 indication

Product
Midodrine